Edwards Lifesciences Corporation $EW Shares Sold by TD Asset Management Inc

TD Asset Management Inc lessened its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 731,078 shares of the medical research company’s stock after selling 12,562 shares during the period. TD Asset Management Inc’s holdings in Edwards Lifesciences were worth $56,856,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. True Wealth Design LLC lifted its stake in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. NewSquare Capital LLC raised its stake in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Rakuten Securities Inc. lifted its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Hantz Financial Services Inc. grew its stake in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in shares of Edwards Lifesciences in the third quarter valued at about $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 67,804 shares of company stock valued at $5,711,242 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EW. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Finally, National Bank Financial set a $92.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Price Performance

NYSE:EW opened at $85.83 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a 50 day moving average price of $82.72 and a 200-day moving average price of $81.16. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The firm has a market cap of $49.81 billion, a price-to-earnings ratio of 46.90, a price-to-earnings-growth ratio of 2.18 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period last year, the company posted $0.59 earnings per share. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.